Xenetic Biosciences (XBIO) Stock Analysis & AI Equity Report
Xenetic Biosciences (XBIO) overview
Xenetic Biosciences (XBIO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 3.0m and operating profit of USD -2.8m; the year-end share price was 2.17 USD and market capitalisation was USD 5.0m. Xenetic Biosciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Xenetic Biosciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Xenetic Biosciences
Xenetic Biosciences is a biopharmaceutical company developing immuno-oncology technologies for difficult-to-treat cancers. Its proprietary DNase technology is designed to target neutrophil extracellular traps, which can contribute to cancer growth, metastasis, and resistance to treatment. The company is advancing a systemic DNase program toward clinical study in people with locally advanced or metastatic solid tumors, initially focusing on pancreatic, colorectal, and other gastrointestinal cancers.
Generate the Xenetic Biosciences report
Xenetic Biosciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Xenetic Biosciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Xenetic Biosciences
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.